The Effect of Everolimus on Subependymal Giant Cell Astrocytoma (SEGA) in Children with Tuberous Sclerosis Complex

Overview

Journal Iran J Child Neurol

Specialty Pediatrics

Date 2021 Nov 16

PMID 34782838

Citations 3

Authors

Hassan Bakhtiary

Mohammad Barzegar

Shadi Shiva

Bita Poorshiri

Parisa Hajalioghli

Hamideh Herizchi Ghadim

Affiliations

Soon will be listed here.

Abstract

Objective: Subependymal Giant Cell Astrocytomas (SEGAs) are slow-growing glioneuronal tumors typically found around the ventricles of the brain, particularly near the foramen of Monro in 15%-20% of patients with tuberous sclerosis complex (TSC). Surgical resection is the standard treatment for these symptomatic tumors. The mTOR inhibitor everolimus can be regarded as an alternative treatment for SEGAs due to the complications of surgery. The present study primarily aimed to specify the effect of everolimus on SEGA volume change before and after treatment. The secondary objective was to determine the effect of this drug on renal angiomyolipoma (AML), skin lesions, and seizures in TSC patients.

Materials & Methods: This pre- and post-treatment clinical trial was performed on 14 children (eight females and six males with a mean age of 10 years) previously diagnosed with TSC based on the diagnostic criteria. The subjects received oral everolimus at a dose of 3 mg/m for at least six months.

Results: Half of the patients had more than 30% of volume loss in SEGA, and in 28.5% of them, a ≥ 50% reduction in SEGA volume was observed (P=0.01). Moreover, 92.9% of the patients had a ≥ 50% decrease in the frequency of seizures (P=0.000). The response rate in AML and skin lesions was 14.2% and 50%, respectively.

Conclusion: Everolimus significantly reduced the seizure frequency and SEGA volume in the subjects; hence, it can be used as a potential alternative treatment for symptomatic SEGA in TSC patients.

Citing Articles

Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy.

Zafar A, Khan M, Abu J, Naeem A Mol Biol Rep. 2024; 51(1):219.

PMID: 38281269 PMC: 10822809. DOI: 10.1007/s11033-023-09096-8.

diagnosed by next-generation sequencing of bronchoscopic alveolar lavage fluid: A case report and review of literature.

Cheng Q, Shen H, Dong Z, Zhang Q, Wang Y, Yan J World J Clin Cases. 2023; 11(4):866-873.

PMID: 36818625 PMC: 9928697. DOI: 10.12998/wjcc.v11.i4.866.

Nervous system (NS) Tumors in Cancer Predisposition Syndromes.

Patil P, Pencheva B, Patil V, Fangusaro J Neurotherapeutics. 2022; 19(6):1752-1771.

PMID: 36056180 PMC: 9723057. DOI: 10.1007/s13311-022-01277-w.

References

Franz D, Budde K, Kingswood J, Belousova E, Sparagana S, De Vries P . Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies. J Eur Acad Dermatol Venereol. 2018; 32(10):1796-1803. DOI: 10.1111/jdv.14964. View

Curatolo P, Bjornvold M, Dill P, Ferreira J, Feucht M, Hertzberg C . The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions. Drugs. 2016; 76(5):551-65. DOI: 10.1007/s40265-016-0552-9. View

Franz D . Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. Biologics. 2013; 7:211-21. PMC: 3797614. DOI: 10.2147/BTT.S25095. View

Wiegand G, May T, Ostertag P, Boor R, Stephani U, Franz D . Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?. Eur J Paediatr Neurol. 2013; 17(6):631-8. DOI: 10.1016/j.ejpn.2013.06.002. View

Curatolo P, Moavero R . mTOR Inhibitors in Tuberous Sclerosis Complex. Curr Neuropharmacol. 2013; 10(4):404-15. PMC: 3520048. DOI: 10.2174/157015912804143595. View

Kohrman M . Emerging treatments in the management of tuberous sclerosis complex. Pediatr Neurol. 2012; 46(5):267-75. DOI: 10.1016/j.pediatrneurol.2012.02.015. View

Connolly M, Hendson G, Steinbok P . Tuberous sclerosis complex: a review of the management of epilepsy with emphasis on surgical aspects. Childs Nerv Syst. 2006; 22(8):896-908. DOI: 10.1007/s00381-006-0130-7. View

Cappellano A, Senerchia A, Adolfo F, Paiva P, Pinho R, Covic A . Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex. Childs Nerv Syst. 2013; 29(12):2301-5. DOI: 10.1007/s00381-013-2170-0. View

Franz D, Tudor C, Leonard J, Egelhoff J, Byars A, Valerius K . Lamotrigine therapy of epilepsy in tuberous sclerosis. Epilepsia. 2001; 42(7):935-40. DOI: 10.1046/j.1528-1157.2001.042007935.x. View

10.

Mizuguchi M, Ikeda H, Kagitani-Shimono K, Yoshinaga H, Suzuki Y, Aoki M . Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan. Brain Dev. 2018; 41(1):1-10. DOI: 10.1016/j.braindev.2018.07.003. View

11.

Krueger D, Northrup H . Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013; 49(4):255-65. PMC: 4058297. DOI: 10.1016/j.pediatrneurol.2013.08.002. View

12.

Davies D, de Vries P, Johnson S, McCartney D, Cox J, Serra A . Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011; 17(12):4071-81. DOI: 10.1158/1078-0432.CCR-11-0445. View

13.

Trelinska J, Dachowska I, Baranska D, Stawiski K, Kotulska K, Fendler W . Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study). Pediatr Blood Cancer. 2016; 64(6). DOI: 10.1002/pbc.26347. View

14.

Krueger D, Care M, Holland K, Agricola K, Tudor C, Mangeshkar P . Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010; 363(19):1801-11. DOI: 10.1056/NEJMoa1001671. View

15.

Atkins M, Yasothan U, Kirkpatrick P . Everolimus. Nat Rev Drug Discov. 2009; 8(7):535-6. DOI: 10.1038/nrd2924. View

16.

Napolioni V, Moavero R, Curatolo P . Recent advances in neurobiology of Tuberous Sclerosis Complex. Brain Dev. 2008; 31(2):104-13. DOI: 10.1016/j.braindev.2008.09.013. View

17.

Ng K, Ng S, Parker A . Annual review of children with tuberous sclerosis. Arch Dis Child Educ Pract Ed. 2014; 100(3):114-21. DOI: 10.1136/archdischild-2013-304948. View

18.

Krueger D, Wilfong A, Holland-Bouley K, Anderson A, Agricola K, Tudor C . Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol. 2013; 74(5):679-87. DOI: 10.1002/ana.23960. View

19.

Cai Y, Guo H, Wang W, Li H, Sun H, Shi B . Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial. Orphanet J Rare Dis. 2018; 13(1):43. PMC: 5870799. DOI: 10.1186/s13023-018-0781-y. View

20.

Franz D, Agricola K, Mays M, Tudor C, Care M, Holland-Bouley K . Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol. 2015; 78(6):929-38. PMC: 5063160. DOI: 10.1002/ana.24523. View